Dimensional Fund Advisors LP Has $408.26 Million Position in Stryker Corporation $SYK

Dimensional Fund Advisors LP lowered its stake in shares of Stryker Corporation (NYSE:SYK) by 1.4% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,242,500 shares of the medical technology company’s stock after selling 18,151 shares during the period. Dimensional Fund Advisors LP’s holdings in Stryker were worth $408,258,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of SYK. Godfrey Financial Associates Inc. acquired a new stake in shares of Stryker during the 4th quarter worth about $26,000. Sankala Group LLC acquired a new stake in Stryker during the fourth quarter worth approximately $26,000. United Financial Planning Group LLC acquired a new stake in shares of Stryker during the 3rd quarter worth $27,000. Atlas Capital Advisors Inc. acquired a new stake in Stryker during the fourth quarter worth about $27,000. Finally, DJE Kapital AG bought a new position in Stryker in the fourth quarter valued at approximately $28,000. Institutional investors own 77.09% of the company’s stock.

Stryker Price Performance

Shares of NYSE:SYK opened at $313.89 on Wednesday. The company has a current ratio of 2.11, a quick ratio of 1.25 and a debt-to-equity ratio of 0.62. The stock’s fifty day simple moving average is $313.79 and its two-hundred day simple moving average is $336.20. Stryker Corporation has a 1-year low of $281.00 and a 1-year high of $404.87. The stock has a market cap of $120.33 billion, a PE ratio of 36.33, a price-to-earnings-growth ratio of 2.04 and a beta of 0.77.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). Stryker had a return on equity of 23.42% and a net margin of 13.20%.The firm had revenue of $6.02 billion during the quarter, compared to the consensus estimate of $6.34 billion. During the same period in the previous year, the company posted $2.84 earnings per share. The company’s revenue for the quarter was up 2.6% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, analysts forecast that Stryker Corporation will post 14.99 EPS for the current fiscal year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date of this dividend is Tuesday, June 30th. Stryker’s payout ratio is 40.74%.

Analyst Upgrades and Downgrades

SYK has been the topic of a number of recent analyst reports. Wall Street Zen cut Stryker from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. Wells Fargo & Company decreased their price objective on Stryker from $456.00 to $418.00 and set an “overweight” rating for the company in a report on Friday, May 1st. BTIG Research set a $371.00 price target on shares of Stryker in a report on Monday, July 13th. The Goldman Sachs Group reissued a “neutral” rating and issued a $361.00 price objective on shares of Stryker in a research note on Friday, May 1st. Finally, Canaccord Genuity Group dropped their target price on shares of Stryker from $435.00 to $400.00 and set a “buy” rating on the stock in a research report on Friday, May 1st. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $392.52.

Insider Buying and Selling at Stryker

In other news, VP M Kathryn Fink sold 5,220 shares of the stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $283.85, for a total transaction of $1,481,697.00. Following the completion of the transaction, the vice president directly owned 13,137 shares of the company’s stock, valued at $3,728,937.45. This represents a 28.44% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Ronda E. Stryker sold 310,000 shares of the stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total value of $96,791,300.00. Following the transaction, the director directly owned 1,924,880 shares of the company’s stock, valued at approximately $601,005,282.40. This trade represents a 13.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 323,264 shares of company stock worth $100,659,489 over the last three months. 4.60% of the stock is currently owned by insiders.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.